Giuseppe Curigliano, MD PhD, is Associate Professor of Medical Oncology at University of Milano and the Head of the Division of Early Drug Development at European Institute of Oncology, Italy. He is a clinician and researcher specialising in early drug development for patients with solid tumours with a special commitment on breast cancer. He has been a Member of the ESMO Breast Cancer Faculty since 2001 and is currently the Breast Cancer Faculty Coordinator. He has also served on the Scientific Committee for the St Gallen Conference since 2011, and was the Scientific Chair in St Gallen 2017 and 2019. He will be the Scientifi Chair of St Gallen 2021. He has been an Editorial Board Member for Annals of Oncology since 2014, and serves as Co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, Associate Editor of the European Journal of Cancer, Editor of the Journal of Clinical Oncology. He also serves on the European School of Oncology (ESO) faculty committee. Dr. Curigliano serves ESMO as the Chair of the Nomination Committee and is a Council Member. Since 2016 he is also a member of the ESMO Women for Oncology Committee, ESMO Membership Committee, ESMO Press and Media Affairs Committee and the ESMO Global Policy Committee. He served as the Scientific Chair of the IMPAKT meeting that was held in Brussels in 2014 and as the Breast Cancer (metastatic) Track Chair of the ESMO 2014 meeting in Madrid. He is the Co-Chair of the first ESMO Breast Cancer Congress in 2019. He will chair the 2020 ESMO Breast Cancer Congress. He was awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. He has contributed to over 300 peer-reviewed publications.